Your browser doesn't support javascript.
loading
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos, Meletios A; Schjesvold, Fredrik; Doronin, Vadim; Vinogradova, Olga; Quach, Hang; Leleu, Xavier; Montes, Yolanda Gonzalez; Ramasamy, Karthik; Pompa, Alessandra; Levin, Mark-David; Lee, Cindy; Mellqvist, Ulf Henrik; Fenk, Roland; Demarquette, Hélène; Sati, Hamdi; Vorog, Alexander; Labotka, Richard; Du, Jichang; Darif, Mohamed; Kumar, Shaji.
Afiliação
  • Dimopoulos MA; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. mdimop@med.uoa.gr.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway.
  • Doronin V; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Vinogradova O; Department of Hematology, City Clinical Hospital No. 40, Moscow, Russia.
  • Quach H; SBIHM "City Clinical Hospital n.a. S. P. Botkin of DHM", City Hematologic Center, Moscow, Russia.
  • Leleu X; Department of Haematology, University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia.
  • Montes YG; Pôle Régional de Cancérologie, CHU and Inserm, 1402, Poitiers, France.
  • Ramasamy K; Department of Haematology, Josep Trueta ICO Girona Hospital, Girona, Spain.
  • Pompa A; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
  • Levin MD; Department of Haematology, GenesisCare, Oxford, United Kingdom.
  • Lee C; Division of Hematology and Stem Cell Transplantation, Fondazione Ca'Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
  • Mellqvist UH; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.
  • Fenk R; Department of Haematology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
  • Demarquette H; Department of Internal Medicine, South Elvsborg Hospital, Boras, Sweden.
  • Sati H; Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Dusseldorf, Germany.
  • Vorog A; Centre Hospitaliser de Dunkerque, Dunkerque, France.
  • Labotka R; Department of Haematology, Singleton Hospital, Swansea Bay University Health Board, Swansea, United Kingdom.
  • Du J; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Darif M; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Kumar S; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Blood Cancer J ; 12(1): 9, 2022 01 24.
Article em En | MEDLINE | ID: mdl-35075109
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Compostos de Boro / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Proteassoma / Lenalidomida / Glicina / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Grécia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Compostos de Boro / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Proteassoma / Lenalidomida / Glicina / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Grécia